Welcome to our dedicated page for Heron Therapeutics SEC filings (Ticker: HRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Heron Therapeutics, Inc. filings document financial results, governance matters, executive compensation arrangements, and capital-structure actions for a commercial-stage biotechnology company. Recent Form 8-K reports furnish quarterly and annual operating results, preliminary revenue disclosures, business updates for the Acute Care franchise, and material corporate events.
Proxy and governance filings cover director elections, board committee matters, executive pay, equity-award disclosure, and stockholder voting. Other filings record amendments to employment and change-in-control provisions, board appointments, and stockholder approvals tied to potential common-stock issuance from convertible senior unsecured promissory notes and Series A Convertible Preferred Stock.
Heron Therapeutics (HRTX) granted new equity awards to its Chief Operating Officer, Mark Earl Hensley. On January 30, 2026, he received 188,315 restricted stock units (RSUs) and 188,314 performance stock units (PSUs), each convertible into common stock on a one-for-one basis.
The RSUs vest in 16 equal quarterly installments starting one quarter after the grant date. The PSUs follow the same quarterly schedule but also depend on achieving a net product sales revenue target for the fiscal year ending December 31, 2026, as reported in the company’s Form 10-K.
Heron Therapeutics director Adam Morgan reported an equity grant and updated holdings. On January 30, 2026, he acquired 53,960 shares of common stock at a price of $0 through restricted stock units that vest in full on January 30, 2027. After this grant, he directly beneficially owns 123,737 shares of common stock.
An additional 8,753,290 shares of common stock are reported as indirectly owned by Velan Capital Master Fund LP. Mr. Morgan may be deemed to beneficially own these securities through related entities but expressly disclaims beneficial ownership except to the extent of his pecuniary interest.
Heron Therapeutics EVP and CFO Ira Duarte reported an automatic conversion of restricted stock units into common shares. On January 31, 2026, 11,695 restricted stock units were converted into 11,695 shares of common stock at a price of $0 per share under a previously granted equity award.
After this transaction, Duarte directly owned 195,356 shares of common stock and held 140,332 restricted stock units. Each restricted stock unit represents the right to receive one share of common stock, vesting in 16 equal quarterly installments that began on January 31, 2025.
Heron Therapeutics executive William P. Forbes reported the vesting of restricted stock units (RSUs) into common shares. On January 31, 2026, 11,695 RSUs converted into 11,695 shares of common stock at an exercise price of $0.00 per share.
After this transaction, Forbes directly owned 181,773 shares of common stock and 140,332 RSUs. Each RSU represents the right to receive one share of common stock, and the RSUs vest in 16 equal installments beginning one quarter after the January 31, 2025 grant date.
Heron Therapeutics CEO Craig A. Collard, who also serves as a director, reported the vesting and conversion of 34,789 restricted stock units into an equal number of Heron common shares on January 31, 2026 via transaction code M.
Each restricted stock unit represents the right to receive one share of common stock, and these units vest in 16 equal installments beginning one quarter after the January 31, 2025 grant date. Following this transaction, Collard directly holds 571,710 shares of common stock and 417,464 restricted stock units, reflecting his ongoing equity compensation in the company.
The Vanguard Group filed a Schedule 13G reporting a passive ownership stake in Heron Therapeutics Inc. As of December 31, 2025, Vanguard reported beneficial ownership of 9,820,384 shares of Heron Therapeutics common stock, representing 5.35% of the outstanding class.
Vanguard reported no sole voting or dispositive power, with 1,238,163 shares subject to shared voting power and 9,820,384 shares subject to shared dispositive power. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Heron Therapeutics.
The document notes that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries or business divisions that pursue the same investment strategies may in the future report beneficial ownership separately on a disaggregated basis.
Heron Therapeutics executive William P. Forbes reported a routine equity vesting transaction. On 01/19/2026, 3,875 restricted stock units converted into an equal number of shares of Heron Therapeutics common stock, at an exercise price of $0.00 per unit. Following this conversion, Forbes directly held 30,994 restricted stock units and 170,078 shares of common stock. The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the original grant date of 01/19/2024, reflecting ongoing equity-based compensation rather than an open-market share sale.
Heron Therapeutics EVP and Chief Financial Officer Ira Duarte reported the vesting of restricted stock units and corresponding acquisition of common stock. On 01/19/2026, 3,875 restricted stock units were converted into 3,875 shares of common stock at a price of $0 per share in a transaction coded "M," which indicates an exercise or conversion. Following this transaction, Duarte directly held 183,661 shares of Heron Therapeutics common stock and 30,994 restricted stock units.
The footnotes explain that each restricted stock unit represents a right to receive one share of common stock and that the units vest in 16 equal quarterly installments starting one quarter after the grant date of 01/19/2024. This reflects routine equity compensation vesting for a senior executive rather than an open-market purchase or sale.
Heron Therapeutics, Inc. Chief Executive Officer Craig A. Collard reported an RSU vesting and share acquisition on 01/19/2026. A total of 13,797 restricted stock units were converted at an exercise price of $0 into 13,797 shares of common stock, reflecting previously granted equity compensation rather than an open-market purchase.
Each restricted stock unit represents a contingent right to receive one share of common stock, and these RSUs vest in 16 equal quarterly installments beginning one quarter after the 01/19/2024 grant date. Following this transaction, Collard directly held 110,375 restricted stock units and 536,921 shares of common stock.
Heron Therapeutics, Inc. filed a current report to share that it has issued a press release with preliminary financial results for the three months ended December 31, 2025 and for full-year 2025. The company furnished this press release as Exhibit 99.1 under a Regulation FD disclosure item, meaning it is being provided for informational purposes and is not treated as formally filed for liability purposes under Section 18 of the Exchange Act. The company also notes that this information will only be incorporated into other securities filings if specifically referenced.